Author(s): Akanksha Shailesh Mane

Email(s): akankshamane110@gmail.com

DOI: 10.52711/2321-5836.2024.00018   

Address: Akanksha Shailesh Mane
Parvar Rural Educational Society of Pharmacy (For Woman’s) Chincholi, Sinnar, Nashik.
*Corresponding Author

Published In:   Volume - 16,      Issue - 2,     Year - 2024


ABSTRACT:
The lymphatic system, an essential part of the body's immune system, is the source of a wide range of blood malignancies known as non-Hodgkin’s lymphoma (NHL). NHL is a diverse group of lymphoid cancers, unlike Hodgkin's lymphoma, which is identified by the presence of Reed-Sternberg cells. It is a complicated and multidimensional disease that is the seventh most frequent cancer in the world, with a number of subgroups. The most common cause of NHL is unchecked proliferation of white blood cells called lymphocytes, which can result in tumor formation in lymph nodes, bone marrow, or other lymphatic tissues. A compromised immune system, exposure to specific viruses, a genetic predisposition, and exposure to specific chemicals or radiation are risk factors for NHL, yet the exact etiology of the disease is still unknown.NHL symptoms can vary greatly and include skin rash, fever, night sweats, swollen lymph nodes, and unexplained weight loss. To identify the exact subtype and stage of the disease, a number of physical examinations, imaging tests, and biopsies are used in the diagnosis process.NHL treatment is based on the subtype, stage, and unique patient characteristics. Chemotherapy, radiation, targeted therapies, and immunotherapy are examples of common therapies. In some circumstances, stem cell transplants might be explored. Early diagnosis and individualized therapy are essential for improving outcomes, and the treatment option is customized to the patient's particular set of circumstances. Because of its heterogeneous character and demand for customized treatment plans, non-Hodgkin's lymphoma presents a serious medical problem. The development of more potent treatments and an improved prognosis for those afflicted by this intricate and frequently fatal illness depend on ongoing research and developments in our understanding of the underlying biology of NHL.


Cite this article:
Akanksha Shailesh Mane. Non-Hodgkins Lymphoma: A Comprehensive Guide. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):99-6. doi: 10.52711/2321-5836.2024.00018

Cite(Electronic):
Akanksha Shailesh Mane. Non-Hodgkins Lymphoma: A Comprehensive Guide. Research Journal of Pharmacology and Pharmacodynamics. 2024;16(2):99-6. doi: 10.52711/2321-5836.2024.00018   Available on: https://rjppd.org/AbstractView.aspx?PID=2024-16-2-7


REFERENCES:
1.    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998 Aug; 16(8): 2780-95.
2.    Nur Kuswanti, Sri Widyarti, Widodo Widodo, Muhaimin Rifa. Cytotoxicity of Ethanolic Extract of Plumeria rubra L. Stem bark to Cancer Cells and Lymphocytes. Research J. Pharm. and Tech. 2018; 11(12): 5545-5550. doi: 10.5958/0974-360X.2018.01009.0
3.    Bowzyk Al-Naeeb A, Ajithkumar T, Behan S, Hodson DJ. Non-Hodgkin lymphoma. BMJ. 2018; 362: k3204.  
4.    Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma-A review. Acta Oncol. 2006; 45:258–71.  
5.    Kolokotronis A, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, et al. Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: A clinical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99:303–10.
6.    Sahithi Alaghari, Kumar Sai Sailesh. Association of Neutrophil/Lymphocyte (N/L) Ratio and Spatial and Verbal Memory in Females. Research J. Pharm. and Tech. 2018; 11(12): 5337-5339. doi: 10.5958/0974-360X.2018. 00971.X
7.    Tg Fatimah Murniwati Tengku Muda, Zul Izhar Mohd Ismail, Shaharudin Abdullah, Nordin Bin Simbak, Mainul Haque. The Effects of Honey on Inflammatory Cells in Cigarette Smoke Affected Lungs in Rats: A Preliminary Study. Research J. Pharm. and Tech. 2014; 7(12): 1382-1386.
8.    Swerdlow SH, et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Fourth Edition. Lyon, France: International Agency for Research on Cancer. 2008.
9.    Feller AL, Diebold J, editors. Histopathology of Nodal and extra nodal Hodgkin Lymphoma. 3rd ed. Springer; 2004. Extra Nodal Lymphoma; pp. 212–4.
10.    Cancer I Af Ro. Globocan. Cancer Incidence, Mortality and Prevalence Worldwide. In: FerlayJ, Bray P, Pisani P, Parkin DM, editors. Lyon: IARCPress; 2001.
11.    Cancer Incidence in Sweden2003.Stockholm:2005.
12.    Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001; 2: 533-43.
13.    Coleman MP, EsteveJ, Damiecki P, Arslan A, Renard H. Trends in cancer incidence and mortality. IARCSci Publ. 1993; 1:806.
14.    BarisD, ZahmSH. Epidemiology of lymphomas. Curr Opin Oncol. 2000; 12:  383-94.
15.    Hakulinen T, Andersen A, Malker B, Pukkala E, Schou G, Tulinius H. Trends in cancer incidence in the Nordic countries. A collaborative studyof the five Nordic Cancer Registries. Acta Pathol Microbiol Immunol Scand Suppl 1986; 288: 1- 151.
16.    Zheng T, Mayne ST, Boyle P, Holford TR, Liu WL, Flannery J. Epidemiology of non-Hodgkin lymphoma in Connecticut. 1935-1988. Cancer. 1992; 70:  840- 9.
17.    Cancer Incidence in Sweden. 2003. Stockholm: 2005.
18.    Registries, AoNC. NORDCAN. Copenhagen : 2004.
19.    Devesa SS, Fears T. Non-Hodgkin’s lymphoma time trends: United States and International Data. Cancer Res. 1992; 52: S5432-4
20.    BanksPM.Changes Indiagnosis of non-Hodgkin’s lymphomas over time. Cancer Res. 1992; 52: S5453-5.
21.    Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin’s lymphoma incidence. Cancer Res. 1992; 52:  S5566-9.
22.    Jiang L, Li N. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis. 2020 Nov; 23(4): 515-529.  
23.    Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version". NCI. 3 August 2016. Archived from the original on 16 August 2016. Retrieved 13 August 2016.
24.    Audebert A. Women with endometriosis: are they different from others]". Gynécologie, Obstétrique and Fertilité (in French). 2005; 33(4): 239–46. doi: 10.1016/j.gyobfe.2005.03.010. PMID 15894210.
25.    Audebert A. Women with endometriosis: are they different from others]". Gynécologie, Obstétrique and Fertilité (in French). 2005; 33(4): 239–46. doi: 10.1016/j.gyobfe.2005.03.010. PMID 15894210.
26.    Somigliana E, Vigano' P, Parazzini F, Stoppelli S, Giambattista E, Vercellini P. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecologic Oncology. 2006; 101(2): 331–41. doi: 10.1016/j.ygyno.2005.11.033. PMID 16473398.
27.    Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K. Spectrum of Epstein-Barr virus-related diseases: A pictorial review. Japanese Journal of Radiology. 2009; 27(1): 4–19. doi:10.1007/s11604-008-0291-2. PMID 19373526. S2CID 6970917.
28.    Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. Journal of Hepatology. 2013; 59(1): 169–177. doi: 10.1016/j.jhep.2013.03.018. PMID 235420
29.    Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, et al.  Non-AIDS-defining cancers among HIV-infected people. European Review for Medical and Pharmacological Sciences. 2012; 16(10): 1377–88. PMID 2310465
30.    Kramer S, Hikel SM, Adams K, Hinds D, Moon K. Current Status of the Epidemiologic Evidence Linking Polychlorinated Biphenyls and Non-Hodgkin Lymphoma, and the Role of Immune Dysregulation. Environmental Health Perspectives. 2012; 120(8): 1067–75. doi:10.1289/ehp.1104652. PMC 3440083. PMID 22552995.
31.    Zani C, Toninelli G, Filisetti B, Donato F. Polychlorinated biphenyls and cancer: an epidemiological assessment. J. Environ. Sci. Health C. 2013; 31(2): 99–144. doi:10.1080/10590501.2013.782174. PMID 23672403. S2CID 5294247.
32.    Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K. Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls. Lancet Oncology. 2013; 14(4): 287–288. doi:10.1016/s1470-2045(13)70104-9. PMID 23499544
33.    ki (11): 4563. doi:10.1182/blood. V104.11.4563.4563. ISSN 0006-4971.
34.    Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. Journal of Hepatology. 2013; 59(1): 169–177. doi: 10.1016/j.jhep.2013.03.018. PMID 23542089
35.    Jiang L, Li N. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy. Angiogenesis. 2020 Nov; 23(4): 515-529.  
36.    Slap GB, Connor JL, Wigton RS, Schwartz JS. Validation of a model to identify young patients for lymph node biopsy. JAMA. 1986 May 23-30; 255(20): 2768-73.  
37.    Steinfort DP, Conron M, Tsui A, Pasricha SR, Renwick WE, Antippa P, Irving LB. Endobronchial ultrasound-guided transbronchial needle aspiration for the evaluation of suspected lymphoma. J Thorac Oncol. 2010 Jun; 5(6): 804-9.  
38.    Kanchan R. Pagar, Mukta R. Mahale. A Review on Brain Tumour, Etiology and Treatment. Asian Journal of Pharmaceutical Research. 2023; 13(1): 51-4. doi: 10.52711/2231-5691.2023.00010.
39.    Zainab A. Ouda, Abdlamer N. Kaloub, Abdulsahib K. Ali. Assessment of DNA Damage in Lymphocytes of Radiation Workers at Al-Tuwaitha Site using Nuclear Division Index and Hypoxanthine guanine phosphoribosyl transferase (HPRT). Research J. Pharm. and Tech. 2018; 11(7): 2855-2858. doi: 10.5958/0974-360X.2018.00526.7
40.    C. N. Hemalatha, N. Janani, S. Vanishree, N. Harikrishnan. Role of Histone Deacetylase (HDAC) Inhibitors for the Treatment of Cutaneous T-Cell Lymphoma (CTCL). Research J. Pharm. and Tech. 2020; 13(6): 2963-2965. doi: 10.5958/0974-360X.2020.00524.7
41.    Sara jawadkadhem, Abdul Sahib K. Ali, Abdul-Ameer N. AL_rikabi. Compartment Between Breast Cancer Patient Undergoing Chemotherapy and Healthy Women by Cytokinesis-block Micronucleus test and Nuclear Division Index. Research J. Pharm. and Tech. 2018; 11(2):705-710. doi: 10.5958/0974-360X.2018.00133.6
42.    Yogita R Mandlik. Immunotherapy, A type of Cancer Treatment. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(4): 282-284. doi: 10.5958/0975-4377.2020.00046.4
43.    Yogita R Mandlik. Immunotherapy, A type of Cancer Treatment. Res. J. Pharma. Dosage Forms and Tech. 2020; 12(4): 282-284. doi: 10.5958/0975-4377.2020.00046.4
44.    Shrada. B. Kumar, Dhanraj. M. Role of Vitamin C in Body Health. Research J. Pharm. and Tech. 2018; 11(4): 1378-1380. doi: 10.5958/0974-360X.2018.00257.3
45.    Zapater E, Bagán JV, Carbonell F, Basterra J. Malignant lymphoma of head and neck. Oral Dis. 2010; 16: 119–28.  
46.    Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2): 169-75.
47.    Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and risk factors of venous thromboembolic events in lymphoma. Am J Med. 2010 Oct; 123(10): 935-41.  
48.    Gertz MA, Anagnostopoulos A, Anderson K, et al.: Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30(2): 121-6.
49.    Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al.: Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007; 25(22): 3344-9.
50.    Treon SP, Branagan AR, Ioakimidis L, et al.: Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009; 113(16): 3673-8.
51.    Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013; 31(3): 301-7.
52.    Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis from the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022; 40(1): 52-62.
53.    Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 Mar 13; 370(11): 1008-18.
54.    Dreyling M, Santoro A, Mollica L, Leppä S, et al. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017 Dec 10; 35(35): 3898-3905.
55.    Flinn IW, Miller CB, Ardeshna KM, Tetreault S, et al. DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients with Refractory Indolent Non-Hodgkin Lymphoma. J Clin Oncol. 2019 Apr 10; 37(11): 912-922.

Recomonded Articles:

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, Das, GC Nanda.

DOI: Not Available         Access: Open Access Read More

Author(s): M Lavanya, Asish Bhaumik, A Gopi Reddy, Ch Manasa, B Kalyani, S Sushmitha

DOI: 10.5958/2321-5836.2016.00012.4         Access: Open Access Read More

Author(s): Purnendu Panda, Banamali Das, DS Sahu, SK Meher, Bikartana Das, GC Bhuyan, Abhijit Joshi MM Rao.

DOI: 10.5958/2321-5836.2015.00027.0         Access: Open Access Read More

Author(s): PM.Patil, PD Chaudhari, Megha Sahu , NJ Duragkar.

DOI: Not Available         Access: Open Access Read More

Author(s): Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tambe

DOI: 10.52711/2321-5836.2022.00008         Access: Closed Access Read More

Author(s): C. H. Praveena, K. Pramod, K. C. Ajithkumar

DOI: 10.5958/2321-5836.2016.00026.4         Access: Open Access Read More

Author(s): Patil SM, Maske AP Sapkale GN, Kure AB.

DOI: Not Available         Access: Open Access Read More

Author(s): Rupali Kirtawade, Pallavi Salve, Chhotaram Seervi, Anita Kulkarni and Pandurang Dhabale.

DOI: Not Available         Access: Open Access Read More

Author(s): Roshan S, Abdullah Khan, Sadath Ali, Tazneem B.

DOI: Not Available         Access: Open Access Read More

Author(s): Roshan S, Tazneem B, Abdullah Khan, Ali.

DOI: Not Available         Access: Open Access Read More

Author(s): Hina Kausar, Mohammed Ubaid-Ur-Rahaman.

DOI: Not Available         Access: Open Access Read More

Author(s): Harshit Rana, Ravi Kumar, Aarti Chopra, Sweta Pundir, Girendra Kumar Gautam, Gautam Kumar

DOI: 10.52711/2321-5836.2022.00009         Access: Closed Access Read More

Author(s): John Masih, Shukla P, Thakur Amit K , Painkara US.

DOI: Not Available         Access: Open Access Read More

Author(s): Ganesh G. Dhakad, Bhagyashri O. Fate, Amruta R. Pandav, Abhijit V. Shrirao, N. I. Kochar, A. V. Chandewar

DOI: 10.52711/2321-5836.2023.00016         Access: Closed Access Read More

Author(s): Rohan Pal, Ritam Ghosh, Banibrata Acharyya, Rajat Subhra Saha, Sudipta Dey, Arpita Nandy, Arin Bhattacharjee

DOI: 10.52711/2321-5836.2023.00032         Access: Closed Access Read More

Author(s): Gayatri Made, Jyothi Swapna Raparthi, Vinod Kumar Mugada, Srinivasa Rao Yarguntla

DOI: 10.52711/2321-5836.2023.00037         Access: Closed Access Read More

Author(s): R. Santhoshkumar, K. R Sathyaramanan, N. Venkateswaramurthy

DOI: 10.52711/2321-5836.2023.00030         Access: Closed Access Read More

Author(s): Akanksha Shailesh Mane

DOI: 10.52711/2321-5836.2024.00018         Access: Closed Access Read More


Recent Articles




Tags